Phen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Founded in 2011, Phen’X Technologies is specialized in medical subcontracting of implants and instruments for dental, maxillofacial and orthopedic applications. With two production sites in France and Portugal, the company manufactures a wide range of components to support surgeons in dental implantology, facial remodeling and orthopedics. The firm also assists its clients in industrialization projects, from the realization of 3D plans and prototypes to the machining of mass-produced parts.
Ciclad is a long-standing, independent private equity investor supporting the growth of small and mid-sized companies in France and abroad. Established in 1988, Ciclad has invested alongside more than 180 executives and management teams. It is involved in buy-outs and capital strengthening, particularly complex transactions such as spin-offs and carveouts, in contexts of strong development – organic growth and build-up – and turnarounds.
Oaklins’ team in France acted as the exclusive financial advisor to the shareholders of Phen’X Technologies in this LBO.
Talk to the deal team
Related deals
iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn moreQuantum Base Holdings plc has completed its official admission to AIM
Quantum Base began trading on the London Stock Exchange’s AIM market under the ticker QUBE following a US$6.4 million (£4.8 million) fundraising round. The company develops Q-ID tags, a quantum-based authentication technology designed to prevent counterfeiting by leveraging atomic-level randomness. Proceeds from the listing will fund product development and commercial expansion, including new operational and commercial hires.
Learn morePharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn more